Brazilian guidelines for the diagnosis and treatment of postmenopausal osteoporosis

Publication date: Available online 21 August 2017
Source:Revista Brasileira de Reumatologia (English Edition)

Author(s): Sebastião Cézar Radominski, Wanderley Bernardo, Ana Patrícia de Paula, Ben-Hur Albergaria, Caio Moreira, Cesar Eduardo Fernandes, Charlles H.M. Castro, Cristiano Augusto de Freitas Zerbini, Diogo S. Domiciano, Laura M.C. Mendonça, Luciano de Melo Pompei, Mailze Campos Bezerra, Marco Antônio R. Loures, Maria Celeste Osório Wender, Marise Lazaretti-Castro, Rosa M.R. Pereira, Sergio Setsuo Maeda, Vera Lúcia Szenjenfeld, Victoria Z.C. Borba

Osteoporosis is the leading cause of fractures in the population older than 50 years. This silent disease affects primarily postmenopausal women and the elderly, and the morbidity and mortality rates are high. The main goal of treating osteoporosis is the prevention of fractures. The identification of populations at risk through early diagnosis and treatment is essential. The last Brazilian guideline for the treatment of postmenopausal osteoporosis was elaborated in 2002. Since then, new strategies for diagnosis and risk stratification have been developed, and drugs with novel action mechanisms have been added to the therapeutic arsenal. The Osteoporosis and Osteometabolic Diseases Committee of the Brazilian Society of Rheumatology, in conjunction with the Brazilian Medical Association and other Societies, has developed this update of the guidelines for the treatment of postmenopausal osteoporosis according to the best scientific evidence available. This update is intended for professionals in many medical and health specialties involved in the treatment of osteoporosis, for physicians in general and for health-related organizations.

Comments are closed.